Building the niche: The role of the S100 proteins in metastatic growth

Seminars in Cancer Biology

Volumn 22, Issue 3, 2012, Pages 216-225

  Lukanidin, Eugene ^a   Sleeman, Jonathan P ^b,c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

Inflammation; Metastasis; Metastatic niche; Microenvironment; S100 family

Indexed keywords

CALCIUM BINDING PROTEIN; CALGRANULIN A; CALGRANULIN B; CALVASCULIN; CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 4; FOCAL ADHESION KINASE; GELATINASE A; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; PROTEIN S 100; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADAPTIVE IMMUNITY; CANCER CELL; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL COMMUNICATION; CIRCULATING TUMOR CELL; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EXTRACELLULAR MATRIX; GENE; HUMAN; INFLAMMATION; INNATE IMMUNITY; LOX GENE; METASTASIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; HUMANS; INFLAMMATION; NEOPLASM METASTASIS; NEOPLASMS; S100 PROTEINS; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84861191800     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.02.006     Document Type: Review

References (194)

1. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
2. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252.
3. Polyak K., Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2010, 2:a003244.
4. Langley R.R., Fidler I.J. The seed and soil hypothesis revisited the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011, 128:2527-2535.
5. Sleeman J.P., Nazarenko I., Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer 2011, 128:2511-2526.
6. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009, 9:285-293.
7. Salama I., Malone P.S., Mihaimeed F., Jones J.L. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34:357-364.
8. Xing F., Saidou J., Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci 2010, 15:166-179.
9. Egeblad M., Littlepage L.E., Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol 2005, 70:383-388.
10. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7:131-142.
11. Tse J.C., Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 2007, 101:816-829.
12. Direkze N.C., Hodivala-Dilke K., Jeffery R., Hunt T., Poulsom R., Oukrif D., et al. Bone marrow contribution to tumor associated myofibroblasts and fibroblasts. Cancer Res 2004, 64:8492-8495.
13. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
14. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
15. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
16. Erez N., Coussens L.M. Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer 2011, 128:2536-2544.
17. Mueller M.M., Fusenig N.E. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849.
18. Ruegg C. Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. J Leukoc Biol 2006, 80:682-684.
19. Luo A., Kong J., Hu G., Liew C.C., Xiong M., Wang X., et al. Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene 2004, 23:1291-1299.
20. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759.
21. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37.
22. Kawai O., Ishii G., Kubota K., Murata Y., Naito Y., Mizuno T., et al. Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV non-small cell lung cancer. Cancer 2008, 113:1387-1395.
23. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
24. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58:3491-3494.
25. Brigati C., Noonan D.M., Albini A., Benelli R. Tumors and inflammatory infiltrates: friends or foes. Clin Exp Metastasis 2002, 19:247-258.
26. Bromwich E.J., McArdle P.A., Canna K., McMillan D.C., McNicol A.M., Brown M., et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003, 89:1906-1908.
27. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
28. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
29. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
30. Shojaei F., Singh M., Thompson J.D., Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci USA 2008, 105:2640-2645.
31. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181:5791-5802.
32. Yan H.H., Pickup M., Pang Y., Gorska A.E., Li Z., Chytil A., et al. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res 2010, 70:6139-6149.
33. Granot Z., Henke E., Comen E.A., King T.A., Norton L., Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011, 20:300-314.
34. Kusmartsev S., Gabrilovich D.I. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006, 55:237-245.
35. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006, 16:53-65.
36. Bunt S.K., Yang L., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007, 67:10019-10026.
37. Song X., Krelin Y., Dvorkin T., Bjorkdahl O., Segal S., Dinarello C.A., et al. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 2005, 175:8200-8208.
38. Movahedi K.M., Guilliams J., Van den Bissche R., Van den Bergh R., De Baetselier P., Van Ginderachter J.A., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
39. Bunt S.K., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006, 176:284-290.
40. Connolly M.K., Mallen-St Clair J., Bedrosian A.S., Malhotra A., Vera V., Ibrahim J., et al. Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. J Leukoc Biol 2010, 87:713-725.
41. Mantovani A. Cancer: inflaming metastasis. Nature 2009, 457:36-37.
42. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., et al. Altered recognition of antigen is a novel mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007, 13:828-835.
43. Bhowmick N.A., Moses H.L. Tumor-stroma interactions. Curr Opin Genet Dev 2005, 15:97-101.
44. Radisky D., Hagios C., Bissell M.J. Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 2001, 11:87-95.
45. Robinson S.C., Coussens L.M. Soluble mediators of inflammation during tumor development. Adv Cancer Res 2005, 93:159-187.
46. Zlotnik A., Burkhardt A.M., Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011, 11:597-606.
47. Liekens S., Schols D., Hatse S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 2010, 16:3903-3920.
48. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
49. Denko N.C., Fontana L.A., Hudson K.M., Sutphin P.D., Raychaudhuri S., Altman R., et al. Investigating hypoxic tumor physiology through gene expression pattern. Oncogene 2003, 22:5907-5914.
50. Wong C.C., Gilkes D.M., Zhang H., Chen J., Wei H., Chaturvedi P., et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 2011, 108:16369-16374.
51. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
52. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
53. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
54. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, I:571-573.
55. Luzzi K.J., MacDonald I.C., Schmidt E.E., Kerkvliet N., Morris V.L., Chambers A.F., et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998, 153:865-873.
56. Kienast Y., von Baumgarten L., Fuhrmann M., Klinkert W.E., Goldbrunner R., Herms J., et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010, 16:116-122.
57. Rosenow F., Ossig R., Thormeyer D., Gasmann P., Schluter K., Brunner G., et al. Integrins as antimetastatic targets of RGD-independent snake venom components in liver metastasis. Neoplasia 2008, 10:168-176.
58. Brown D.M., Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 2004, 5:365-374.
59. Laubli H., Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol 2010, 20:169-177.
60. Al-Mehdi A.B., Tozawa K., Fisher A.B., Shientag L., Lee A., Muschel R.J. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 2000, 6:100-102.
61. Fidler I.J. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011, 21:107-112.
62. Shiozawa Y., Pienta K.J., Taichman R.S. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 2011, 17:5553-5558.
63. Shiozawa Y., Pedersen E.A., Havens A.M., Jung Y., Mishra A., Joseph J., et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow occupancy. J Clin Invest 2011, 121:1298-1312.
64. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., MacDonald D.D., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
65. Kaplan R.N., Rafii S., Lyden D. Preparing the 'soil': the premetastatic niche. Cancer Res 2006, 66:11089-11093.
66. Kaplan R.N., Psaila B., Lyden D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med 2007, 13:72-81.
67. Wels J., Kaplan R.N., Rafii S., Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 2008, 22:559-574.
68. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006, 8:1369-1375.
69. Hiratsuka S., Watanabe A., Sakurai Y., Akashi-Takamura S., Ishibashi S., Miyake K., et al. The S100A8-serum amyloid A3-TLR 4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008, 10:1349-1355.
70. Hiratsuka S., Nakamura K., Iwai S., Murakami M., Itoh T., Kijima H., et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2:289-300.
71. Ossowski L., Aguirre-Ghiso J.A. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 2010, 23:41-56.
72. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995, 1:149-153.
73. Wikman H., Vessella R., Pantel K. Cancer micrometastasis and tumour dormancy. Apmis 2008, 116:754-770.
74. Barkan D., Green J.E., Chambers A.F. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 2010, 46:1181-1188.
75. Horak C.E., Lee J.H., Marshall J.C., Shreeve S.M., Steeg P.S. The role of metastasis suppressor genes in metastatic dormancy. Apmis 2008, 116:586-601.
76. Eyles J., Puaux A.L., Wang X., Toh B., Prakash C., Hong M., et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010, 120:2030-2039.
77. McAllister S.S., Gifford A.M., Greiner A.L., Kelleher S.P., Saelzler M.P., Ince T.A., et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005.
78. Foell D., Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004, 50:3762-3771.
79. Masuda K., Masuda R., Neidhart M., Simmen B.R., Michel B.A., Müller-Ladner U., et al. Molecular profile of synovial fibroblasts in rheumatoid arthritis depends on the stage of proliferation. Arthritis Res 2002, 4:R8.
80. Senolt L., Grigorian M., Lukanidin E., Michel B.A., Gay R.E., Gay S., et al. S100A4 (Mts1): is there any relation to the pathogenesis of rheumatoid arthritis. Autoimmun Rev 2006, 5:129-131.
81. Santamaria-Kisiel L., Rintala-Dempsey A.C., Shaw G.S. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 2006, 396:201-214.
82. Fritz G., Botelho H.M., Morozova-Roche L.A., Gomes C.M. Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity. FEBS J 2010, 277:4578-4590.
83. Lackmann M., Cornish C.J., Simpson R.J., Moritz R.L., Geczy C.L. Purification and structural analysis of a murine chemotactic cytokine (CP-10) with sequence homology to S100 proteins. J Biol Chem 1992, 267:7499-7504.
84. Frosch M., Strey A., Vogl T., Wulffraat N.M., Kuis W., Sunderkötter C., et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000, 43:628-637.
85. Rammes A., Roth J., Goebeler M., Klempt M., Hartmann M., Sorg C. Myeloid related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997, 272:9496-9502.
86. Unno M., Kawasaki T., Takahara H., Heizmann C.W., Kizawa K. Refined crystal structures of human Ca(2+)/Zn(2+)-binding S100A3 protein characterized by two disulfide bridges. J Mol Biol 2011, 408:477-490.
87. Moroz O.V., Bronstein I.B., Wilson K.S. The crystal structure of zebrafish S100Z: implications for calcium-promoted S100 protein oligomerisation. J Mol Biol 2011, 411:1072-1082.
88. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003, 60:540-551.
89. Heizmann C.W., Fritz G., Schafer B.W. S100 proteins: structure, functions and pathology. Front Biosci 2002, 7:1356-1368.
90. Tarabykina S., Kriajevska M., Scott D.J., Hill T.J., Lafitte D., Derrick P.J., et al. Heterocomplex formation between metastasis-related protein S100A4 (Mts1) and S100A1 as revealed by the yeast two-hybrid system. FEBS Lett 2000, 475:187-191.
91. Wang G., Zhang S., Fernig D.G., Martin-Fernandez M., Rudland P.S., Barraclough R. Mutually antagonistic actions of S100A4 and S100A1 on normal and metastatic phenotypes. Oncogene 2005, 24:1445-1454.
92. Hobbs J.A., May R., Tanousis K., McNeill E., Mathies M., Gebhardt C., et al. Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol 2003, 23:2564-2576.
93. Grum-Schwensen B., Klingelhofer J., Berg C.H., El-Naaman C., Grigorian M., Lukanidin E., et al. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 2005, 65:3772-3780.
94. Passey R.J., Williams E., Lichanska A.M., Wells C., Hu S., Geczy C.L., et al. A null mutation in the inflammation associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol 1999, 163:2209-2216.
95. Manitz M.P., Horst B., Seeliger S., Strey A., Skryabin B.V., Gunzer M., et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 2003, 23:1034-1043.
96. Schmidt A.M., Hofmann M., Taguchi A., Yan S.D., Stern D.M. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 2000, 26:485-493.
97. Huttunen H.J., Kuja-Panula J., Sorci G., Agneletti A.L., Donato R., Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000, 275:40096-40105.
98. Ghavami S., Rashedi I., Dattilo B.M., Eshraghi M., Chazin W.J., Hashemi M., et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 2008, 83:1484-1492.
99. Loser K., Vogl T., Voskort M., Lueken A., Kupas V., Nacken W., et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 2010, 16:713-717.
100. Srikrishna G., Nayak J., Weigle B., Temme A., Foell D., Hazelwood L., et al. Carboxylated N-glycans on RAGE promote S100A12 binding and signaling. J Cell Biochem 2010, 110:645-659.
101. 2+ signaling in neurons induced by the S100A4 protein. Mol Cell Biol 2006, 26:3625-3638.
102. Klingelhöfer J., Møller H.D., Sumer E.U., Berg C.H., Poulsen M., Kiryushko D., et al. Epidermal growth factor receptor ligands as new extracellular targets for the metastasis-promoting S100A4 protein. FEBS J 2009, 276:5936-5948.
103. Hernan R., Fasheh R., Calabrese C., Frank A.J., Maclean K.H., Allard D., et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003, 63:140-148.
104. Marenholz I., Heizmann C.W., Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004, 322:1111-1122.
105. Gebhardt C., Nemeth J., Angel P., Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006, 72:1622-1631.
106. Heizmann C.W., Ackermann G.E., Galichet A. Pathologies involving the S100 proteins and RAGE. Subcell Biochem 2007, 45:93-138.
107. Malone P.S., Mihaimeed F., Jones J.L. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34:357-364.
108. Moinzadeh P., Breuhahn K., Stutzer H., Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade-results of an explorative CGH meta-analysis. Brit J Cancer 2005, 92:935-941.
109. Jee K.J., Gong G., Ahn S.H., Park J.M., Knuutila S. Gain in 1q is a common abnormality in phyllodes tumours of the breast. Anal Cell Pathol 2003, 25:89-93.
110. Letson G.D., Muro-Cacho C.A. Genetic and molecular abnormalities in tumors of the bone and soft tissues. Cancer Control 2001, 8:239-251.
111. Glinsky G.V., Krones-Herzig A., Glinskii A.B. Malignancy associate regions of transcriptional activation: gene expression profiling identifies common chromosomal regions of a recurrent transcriptional activation in human prostate, breast, ovarian, and colon cancers. Neoplasia 2003, 5:218-228.
112. Emberley E.D., Murphy L.C., Watson P.H. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 2004, 82:508-515.
113. Gebhardt C., Breitenbach U., Tuckermann J.P., Dittrich B.T., Richter K.H., Angel P. Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skincarcinogenesis. Oncogene 2002, 21:4266-4276.
114. Ott H.W., Lindner H., Sarg B., Mueller-Holzner E., Abendstein B., Bergant A., et al. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 2003, 63:7507-7514.
115. Ryckman C., Vandal K., Rouleau P., Talbot M., Tessier P.A. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 2003, 170:3233-3242.
116. Zwadlo G., Bruggen J., Gerhards G., Schlegel R., Sorg C. Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues. Clin Exp Immunol 1988, 72:510-515.
117. Roth J., Burwinkel F., van den Bos C., Goebeler M., Vollmer E., Sorg C. MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. Blood 1993, 82:1875-1883.
118. Arai K., Takano S., Teratani T., Ito Y., Yamada T., Nozawa R. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 2008, 8:243-252.
119. Kusmartsev S., Nagaraj S., Gabrilovich D.I. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005, 175:4583-4592.
120. Pan P.Y., Wang G.X., Yin B., Ozao J., Ku T., Divino C.M., et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid derived suppressor cell development by blockade of SCF function. Blood 2007, 111:219-228.
121. Delano M.J., Scumpia P.O., Weinstein J.S., Coco D., Nagaraj S., Kelly-Scumpia K.M., et al. MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007, 204:1463-1474.
122. Vogl T., Tenbrock K., Ludwig S., Leukert N., Ehrhardt C., van Zoelen M.A., et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007, 13:1042-1049.
123. Chen P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008, 205:2235-2249.
124. Nacken W., Roth J., Sorg C., Kerkhoff C. S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 2003, 60:569-580.
125. Kusmartsev S., Gabrilovich D.I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 2003, 74:186-196.
126. Turovskaya O., Foell D., Sinha P., Vogl T., Newlin R., Nayak J., et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008, 29:2035-2043.
127. Ichikawa M., Williams R., Wang L., Vogl T., Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 2011, 9:133-148.
128. Gebhardt C., Riehl A., Durchdewald M., Nemeth J., Furstenberger G., Muller-Decker K., et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008, 205:275-285.
129. Rosenthal C.J., Sullivan L.M. Serum amyloid A to monitor cancer dissemination. Ann Intern Med 1979, 91:383-390.
130. Malle E., Sodin-Semrl S., Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009, 66:9-26.
131. Tomita T., Sakurai Y., Ishibashi S., Maru Y. Imbalance of Clara cell-mediated homeostatic inflammation is involved in lung metastasis. Oncogene 2011, 30:3429-3439.
132. Badolato R., Wang J.M., Murphy W.J., Lloyd A.R., Michiel D.F., Bausserman L.L., et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994, 180:203-209.
133. Xu L., Badolato R., Murphy W.J., Longo D.L., Anver M., Hale S., et al. A novel biologic function of serum amyloid A: induction of T lymphocyte migration and adhesion. J Immunol 1995, 155:1184-1190.
134. Vallon R., Freuler F., Desta-Tsedu N., Robeva A., Dawson J., Wenner P., et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001, 166:2801-2807.
135. Mitchell T.I., Coon C.I., Brinckerhoff C.E. Serum amyloid A (SAA3) produced by rabbit synovial fibroblasts treated with phorbol esters or interleukin 1 induces synthesis of collagenase and is neutralized with specific antiserum. J Clin Invest 1991, 87:1177-1185.
136. Szlosarek P., Charles K.A., Balkwill F.R. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006, 42:745-750.
137. Grivennikov S.I., Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011, 70:104-108.
138. Banno T., Gazel A., Blumenberg M. Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes. J Biol Chem 2005, 280:18973-18980.
139. Xu K., Geczy C.L. IFN-gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8. J Immunol 2000, 164:4916-4923.
140. Urieli-Shoval S., Linke R.P., Matzner Y. Expression and function of serum amyloid A, a major acutephase protein, in normal and disease states. Curr Opin Hematol 2000, 7:64-69.
141. Ebralidze A., Tulchinsky E., Grigorian M., Afanasyeva A., Senin V., Revazova E., et al. Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family. Genes Dev 1989, 3:1086-1093.
142. Klingelhöfer J., Ambartsumian N.S., Lukanidin E.M. Expression of the metastasis-associated mts1 gene during mouse development. Dev Dyn 1997, 210:87-95.
143. Ford H.L., Zain S.B. Interaction of metastasis associated Mts1 protein with nonmuscle myosin. Oncogene 1995, 10:1597-1605.
144. Cabezón T., Celis J.E., Skibshøj I., Klingelhöfer J., Grigorian M., Gromov P., et al. Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int J Cancer 2007, 121:1433-1444.
145. Klingelhöfer J., Senolt L., Baslund B., Nielsen G.H., Skibshøj I., Pavelka K., et al. Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2007, 56:779-789.
146. Lloyd B.H., Platt-Higgins A., Rudland P.S., Barraclough R. Human S100A4 (p9Ka) induces the metastatic phenotype upon benign tumour cells. Oncogene 1998, 17:465-473.
147. Maelandsmo G.M., Hovig E., Skrede M., Engebraaten O., Flørenes V.A., Myklebost O., et al. Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 1996, 56:5490-5498.
148. Grigorian M., Ambartsumian N., Lykkesfeldt A.E., Bastholm L., Elling F., Georgiev G., et al. Effect of mts1 (S100A4) expression on the progression of human breast cancer cells. Int J Cancer 1996, 67:831-841.
149. Ambartsumian N.S., Grigorian M.S., Larsen I.F., Karlstrom O., Sidenius N., Rygaard J., et al. Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 1996, 13:1621-1630.
150. Davies M.P., Rudland P., Robertson L., Parry E.W., Jolicoeur P., Barraclough R. Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 1996, 13:1631-1637.
151. Platt-Higgins A.M., Renshaw C.A., West C.R., Winstanley J.H., Rudland S., Barraclough R., et al. Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer. Int J Cancer 2000, 89:198-208.
152. Yonemura Y., Endou Y., Kimura K., Fushida S., Bandou E., Taniguchi K., et al. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000, 6:4234-4242.
153. Davies B.R., O'Donnell M., Durkan G.C., Rudland P.S., Barraclough R., Neal D.E., et al. Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol 2002, 196:292-299.
154. Rosty C., Ueki T., Argani P., Jansen M., Yeo C.J., Cameron J.L., et al. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 2002, 160:45-50.
155. Lee W.Y., Su W.C., Lin P.W., Guo H.R., Chang T.W., Chen H.H. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Oncology 2004, 66:429-438.
156. Cho Y.G., Nam S.W., Kim T.Y., Kim Y.S., Kim C.J., Park J.Y., et al. Overexpression of S100A4 is closely related to the aggressiveness of gastric cancer. Apmis 2003, 111:539-545.
157. Helfman D.M., Kim E.J., Lukanidin E., Grigorian M. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 2005, 92:1955-1958.
158. Missiaglia E., Blaveri E., Terris B., Wang Y.H., Costello E., Neoptolemos J.P., et al. Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer 2004, 112:100-112.
159. Ambartsumian N., Klingelhofer J., Grigorian M., Christensen C., Kriajevska M., Tulchinsky E., et al. The metastasis-associated Mts1 (S100A4) protein could act as an angiogenic factor. Oncogene 2001, 20:4685-4695.
160. Novitskaya V., Grigorian M., Kriajevska M., Tarabykina S., Bronstein I., Berezin V., et al. Oligomeric forms of the metastasis-related Mts1 (S100A4) protein stimulate neuronal differentiation in cultures of rat hippocampal neurons. J Biol Chem 2000, 275:41278-41286.
161. Grigorian M., Ambartsumian N., Lukanidin E. Metastasis-inducing S100A4 protein: implication in non-malignant human pathologies. Curr Mol Med 2008, 8:492-496.
162. Kriajevska M.V., Cardenas M.N., Grigorian M.S., Ambartsumian N.S., Georgiev G.P., Lukanidin E.M. Non-muscle myosin heavy chain as a possible target for protein encoded by metastasis-related mts-1 gene. J Biol Chem 1994, 269:19679-19682.
163. Kriajevska M., Fischer-Larsen M., Moertz E., Vorm O., Tulchinsky E., Grigorian M., et al. Liprin beta 1, a member of the family of LAR transmembrane tyrosine phosphatase-interacting proteins, is a new target for the metastasis-associated protein S100A4 (Mts1). J Biol Chem 2002, 277:5229-5235.
164. Grigorian M., Andresen S., Tulchinsky E., Kriajevska M., Carlberg C., Kruse C., et al. Functional significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay. J Biol Chem 2001, 276:22699-22708.
165. Belot N., Pochet R., Heizmann C.W., Kiss R., Decaestecker C. Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton. Biochim Biophys Acta 2002, 1600:74-83.
166. Duarte W.R., Iimura T., Takenaga K., Ohya K., Ishikawa I., Kasugai S. Extracellular role of S100A4 calcium-binding protein in the periodontal ligament. Biochem Biophys Res Commun 1999, 255:416-420.
167. Schmidt-Hansen B., Ornas D., Grigorian M., Klingelhofer J., Tulchinsky E., Lukanidin E., et al. Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 2004, 23:5487-5495.
168. Andersen K., Maelandsmo G.M., Hovig E., Fodstad O., Loennechen T., Winberg J.O. Interleukin-1 alpha and basic fibroblast growth factor induction of matrix metalloproteinases and their inhibitors in osteosarcoma cells is modulated by the metastasis associated protein CAPL. Anticancer Res 1998, 18:3299-3303.
169. Bjornland K., Winberg J.O., Odegaard O.T., Hovig E., Loennechen T., Aasen A.O., et al. S100A4 involvement in metastasis. Deregulation of matrix metalloproteinases and tissue inhibitors metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribizyme. Cancer Res 1999, 59:4702-4708.
170. Strutz F., Zeisberg M., Ziyadeh F.N., Yang C.Q., Kalluri R., Muller G.A., et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002, 61:1714-1728.
171. Olsen C.J., Moreira J., Lukanidin E.M., Ambartsumian N.S. Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts. BMC Cancer 2010, 10:444.
172. O'Connell J.T., Sugimoto H., Cooke V.G., MacDonald B.A., Mehta A.I., LeBleu V.S., et al. VEGF-A and tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA 2011, 108:16002-16007.
173. Oskarsson T., Acharyya S., Zhang X.H., Vanharanta S., Tavazoie S.F., Morris P.G., et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011, 17:867-874.
174. Schmidt-Hansen B., Klingelhofer J., Grum-Schwensen B., Christensen A., Andresen S., Kruse C., et al. Functional significance of metastasis-inducing S100A4 (Mts1) in tumor-stroma interplay. J Biol Chem 2004, 279:24498-24504.
175. Forst B., Hansen M.T., Klingelhofer J., Møller H.D., Nielsen G.H., Grum-Schwensen B., et al. Metastasis-inducing S100A4 and RANTES cooperate in promoting tumor progression in mice. PLoS ONE 2010, 5:e10374.
176. Mishra P., Banerjee D., Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 2011, 89:31-39.
177. Soria G., Ofri-Shahak M., Haas I., Yaal-Hahoshen N., Leider-Trejo L., Leibovich-Rivkin T., et al. Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011, 11:130.
178. Cao Z., Xu X., Luo X., Li L., Huang B., Li X., et al. Role of RANTES and its receptor in gastric cancer metastasis. J Huazhong Univ Sci Technol Med Sci 2011, 31:342-347.
179. Ratajczak J., Wysoczynski M., Hayek F., Janowska-Wieczorek A., Ratajczak M.Z. Membrane-derived microvesicles: important and under appreciated mediators of cell-to-cell communication. Leukemia 2006, 20:1487-1495.
180. Ratajczak J., Miekus K., Kucia M., Zhang J., Reca R., Dvorak P., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20:847-856.
181. Quesenberry P.J., Dooner M.S., Aliotta J.M. Stem cell plasticity revisited: the continuum marrow model and phenotypic changes mediated by microvesicles. Exp Hematol 2010, 38:581-592.
182. Grande C., Tapparo M., Collino F., Vitillo L., Damasco C., Deregibus M.C., et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 2011, 71:5346-5356.
183. Grum-Schwensen B., Klingelhofer J., Grigorian M., Almholt K., Nielsen B.S., Lukanidin E., et al. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. Cancer Res 2010, 70:936-947.
184. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003, 5:31-36.
185. Lotfi R., Lee J.J., Lotze M.T. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother 2007, 30:16-28.
186. Lampinen M., Carlson M., Hakansson L.D., Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004, 59:793-805.
187. Cheadle E.J., Riyad K., Subar D., Rothwell D.G., Ashton G., Batha H., et al. Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res 2007, 13:5719-5728.
188. Hunter M.G., Jacob A., O'Donnell L.C., Agler A., Druhan L.J., Coggeshall K.H., et al. Loss of SHIP and CIS recruitment to the granulocyte colony-stimulating factor receptor contribute to hyperproliferative responses in severe congenital neutropenia/acute myelogenous leukemia. J Immunol 2004, 173:5036-5045.
189. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
190. Mueller M.M. Inflammation in epithelial skin tumours: old stories and new ideas. Eur J Cancer 2006, 42:735-744.
191. Obermueller E., Vosseler S., Fusenig N.E., Mueller M.M. Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte - macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res 2004, 64:7801-7812.
192. Hirbe A.C., Uluckan O., Morgan E.A., Eagleton M.C., Prior J.L., Piwnica-Worms D., et al. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast dependent manner. Blood 2007, 109:3424-3431.
193. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009, 106:6742-6747.
194. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., et al. Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.